| |
.Abacavir/Lamivudine
and Tenofovir/Emtricitabine in Pregnant Women with Hiv: Laboratory and
Clinical Outcomes in an Observational National Study.
Floridia M, Pinnetti C, Ravizza M,
et al
J Acquir Immune Defic Syndr. 2018
Feb 5.
Abstract
Bone density, microarchitecture and tissue quality following
long-term treatment with tenofovir/emtricitabine or abacavir/lamivudine.
Güerri-Fernández R, Molina-Morant D,
et al
J Acquir Immune Defic Syndr.
2017 Apr 7.
Abstract
Evaluation of the Lipid Concentrations after Switching from Antiretroviral
Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir
Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency
Virus-infected Patients.
Arae H, Tateyama M, Nakamura H,
Intern Med.
2016;55(23):3435-3440
Abstract
FULL-TEXT ARTICLE
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for
HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective
Study.
Troya J, Ryan
P, Ribera E, et al
PLoS One. 2016 Oct
11;11(10):e0164455.
Paper
Long-term efficacy and toxicity of
abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens
before 2013 in a French Nationwide Cohort Study.
de Boissieu P, Dramé M, Raffi F, et al
Medicine (Baltimore).
2016 Sep;95(37):e4890.
Abstract
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for
the treatment of HIV-1 infection in naive patients.
Curran A, Rojas J, Cabello A, Troya J,
et al
J Antimicrob Chemother.
2016 Sep 2.
Abstract
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir
Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected
Patients in Clinical Practice.
Lackey P, Mills A, Carpio F, et al
Clin Drug Investig.
2016 Sep 1.
Abstract
Exploratory Analysis for the Evaluation of Estimated
Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching
from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to
Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.
Postorino MC, Quiros-Roldan E,
Maggiolo F, et al
Open AIDS J. 2016 Jul 15;10:136-43.
Abstract
FULL-TEXT ARTICLE
An Indirect Comparison of Efficacy and Safety of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and
Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
M Llibre J, Raffi F, Moyle G,
et al
PLoS One.
2016 May 19;11(5):e0155406.
Paper
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens
in patients with a high viral load.
Flandre P, Pugliese P, Allavena C, et
al
HIV Med.
2016 May;17(5):380-4.
Abstract
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected
Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or
Tenofovir-Emtricitabine Plus Efavirenz.
Calza L, Magistrelli E, Danese I,
et al
Curr HIV Res.
2016;14(1):61-70.
Abstract
Backbone switch to abacavir/lamivudine fixed-dose combination: implications for
antiretroviral therapy optimization.
Fantauzzi A, Floridia M, Falasca F,
et al
New Microbiol. 2015 Oct 20;38(4).
Abstract
Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in
HIV-1 Infection.
Greig SL, Deeks ED.
Drugs.
2015 Feb 20.
Abstract
FULL-TEXT ARTICLE
A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus
Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in
Hypercholesterolemic HIV-1 Infected Individuals.
Moyle GJ, Orkin C, Fisher M, et al
PLoS
One. 2015 Feb 6;10(2):e0116297.
Paper
Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral
Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open
Label, Non-Inferiority Trial.
PLOS ONE Staff.
PLoS One. 2014 Jul 23;9(7):e103925.
Abstract
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a
multicentre experience in antiretroviral therapy-naive and -experienced
patients.
Podzamczer D, Imaz A, Perez I,
et al
J Antimicrob Chemother. 2014 May 15.
Abstract
FULL-TEXT ARTICLE
Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral
Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized,
Open Label, Non-Inferiority Trial.
Wohl DA, Bhatti L, Small CB, et al
PLoS One.
2014 May 13;9(5):e96187.
Paper
Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in
post-marketing surveillance in Japan.
Kurita T, Kitaichi T, Nagao T, et al
Pharmacoepidemiol Drug Saf.
2014 Mar 3.
Abstract
Early Virologic Response to Abacavir/Lamivudine and
Tenofovir/Emtricitabine During ACTG A5202.
Grant PM, Tierney
C, Budhathoki C, et al
HIV Clin Trials. 2013
Nov-Dec;14(6):284-91.
Abstract
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus
efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Moyle
GJ, Stellbrink HJ, Compston J, et al
Antivir Ther.
2013 Jul 31.
Abstract
Pharmacokinetic interactions between
lersivirine and zidovudine, tenofovir disoproxil
fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M, Davis J, Langdon G, et al
Antivir Ther.
2013 Apr 4.
Abstract
Once-daily darunavir/ritonavir and abacavir/lamivudine versus
tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load
of more than 100 000 copies/ml.
Nishijima T, Komatsu H,
Teruya K, et al
AIDS.
2013 Mar 13;27(5):839-42
Abstract
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir
for Treatment-naive Japanese Patients
with HIV-1 Infection: A Randomized Multicenter Trial.
Nishijima T, Takano M, Ishisaka
M, et al
|Intern
Med. 2013;52(7):735-44
Abstract
Novel Kivexa-based regimens in early courses of treatment for HIV infection.
Conway B, Alenezi O, Wong L,
et
al
J Int AIDS Soc.
2012 Nov 11;15(6):18283.
Abstract
Effectiveness and tolerability of abacavir-lamivudine-nevirapine
(ABC/3TC/NVP) in a multicenter cohort of HIV-infected ARV-experienced
patients.
Podzamczer D, Ferrer E, Llibre J,
et al
J Int AIDS Soc. 2012 Nov 11;15(6):18343
Abstract |
Changes in Fat Mitochondrial DNA and Function in Subjects
Randomized to Abacavir/Lamivudine or Tenofovir DF/Emtricitabine with
Atazanavir/Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s,
substudy of A5202.
McComsey GA, Daar ES, O'Riordan , et al
J Infect Dis. 2012
Nov 29.
Abstract
Abacavir/lamivudine vs tenofovir/emtricitabine in virologically
suppressed patients switching from ritonavir-boosted protease inhibitors to
raltegravir.
Martinez E, D'Albuquerque PM, Perez I, et al
AIDS Res Hum Retroviruses. 2012
Aug 23
Abstract
FULL-TEXT ARTICLE
Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing
Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine.
Haskelberg H, Hoy JF, Amin J,
et al
PLoS One.
2012;7(6):e38377
Paper
Inflammation markers after randomization to abacavir/lamivudine or
tenofovir/emtricitabine with efavirenz or
atazanavir/ritonavir: ACTG A5224 s, A5202 substudy.
McComsey GA, Kitch D, Daar ES,
et al
AIDS. 2012 Apr 26
Abstract
Effects of highly active antiretroviral therapy on platelet activating factor
metabolism in naive HIV-infected patients:
ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
Chini M, Tsoupras AB, Mangafas
N,
et al
Int J Immunopathol Pharmacol.
2012 Jan-Mar;25(1):247-58.
Abstract
Changes in body
composition and mitochondrial DNA in HIV-1-infected patients switching
to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a
substudy of the BICOMBO Trial.
Curran A, Martinez E, Podzamczer D, et al
Antivir Ther.
2012 Feb 28.
Abstract |
FULL-TEXT ARTICLE
Predictors of Limb Fat Gain in HIV Positive Patients Following a
Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine.
Martin A, Amin J, Emery S,
et al
PLoS
One.
2011;6(10):e26885
Paper |
Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of
Combination Regimens for
Initial Treatment of HIV: Final Results.
Sax PE, Tierney C, Collier
AC, et al
J Infect Dis. 2011
Oct;204(8):1191-1201.
Abstract
Abacavir and lamivudine for the treatment of human
immunodeficiency virus.
Rizzardini G, Zucchi P.
Expert Opin Pharmacother.
2011 Sep;12(13):2129-38
Abstract
Comparison of abacavir/lamiv
udine and
tenofovir/emtricitabine among treatment-naïve
HIV-infected patients initiating therapy.
Tan DH, Chan K, Raboud J, Cooper C, et al
J Acquir Immune Defic Syndr.
2011 Jun 24.
Abstract
Peripheral and Central Fat Changes in Subjects Randomized to
Abacavir-Lamivudine or
Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG
Study A5224s.
McComsey GA, Kitch D, Sax
PE,
et al
Clin Infect Dis.
2011 Jul;53(2):185-96.
Abstract
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons
Randomized to Receive
Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine
Along With Efavirenz or
Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of
ACTG A5202.
McComsey GA, Kitch D, Daar ES,
et
al
J Infect Dis.
2011 Jun;203(12):1791-801.
Abstract
|
Open-label randomized multicenter selection study of once daily
antiretroviral treatment regimen
comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose
abacavir and Lamivudine.
Honda M, Ishisaka M, Ishizuka N,
et
al
Intern Med.
2011;50(7):699-705.
Abstract
|
Pharmacokinetics and acceptability of once- versus twice-daily
lamivudine and
abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V, Kendall L, Bakeera-Kitaka S, et al
Antivir Ther.
2010;15(8):1115-1124.
Abstract
|
Comparison of Changes in Bone Density and Turnover with
Abacavir-Lamivudine versus
Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from
the ASSERT Study.
Stellbrink HJ, Orkin C, Arribas JR, et al
Clin Infect Dis.
2010 Sep
Abstract |
| |
Randomized Comparison of Renal Effects, Efficacy, and Safety With
Once-Daily
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With
Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From
the ASSERT
Study.
Post FA, Moyle GJ, Stellbrink HJ, et al
J
Acquir Immune Defic Syndr. 2010 Apr 24
Abstract |
|
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy.
Sax PE, Tierney C, Collier AC,
et al
N Engl J Med. 2009 Dec
3;361(23):2230-2240.
Abstract
|
Abacavir and lamivudine combination.
Somboonwit C, Kurtyka D, Paula Velez A.
Expert Opin Drug Metab Toxicol.
2009 Dec;5(12):1599-606.
Abstract
|
Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or
Abacavir-Lamivudine:
A Randomized, 96-Week Trial.
Martin A, Bloch M, Amin J, et al
Clin Infect Dis.
2009 Nov 15;49(10):1591-1601
Abstract |
| |
Randomized, double-blind, placebo-matched, multicenter trial of
abacavir/lamivudine or
tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV
treatment.
Smith KY, Patel P, Fine D, et al
AIDS
2009 Jun 17.
Abstract
|
|
|
A Simplification Trial Switching From Nucleoside Reverse Transcriptase
Inhibitors to Once-Daily
Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in
HIV-1-Infected Patients With Virological
Suppression.
Martínez E, Arranz JA, Podzamczer D,
et al
J Acquir Immune Defic Syndr.
2009 Apr 24.
Abstract
|
Two novel fixed formulations of nucleoside analogues
(tenofovir-emtricitabine, and
abacavir-lamivudine).
Prospective, open study on clinical practice and therapeutic
perspectives, in patients naïve and in
subjects pre-treated with antiretrovirals
Manfred R, Calza L.
Recenti Prog Med.
2008 Oct;99(10):492-501
Abstract |
|
Switching from twice-daily abacavir and lamivudine to the
once-daily fixed-dose combination tablet of
abacavir and lamivudine improves patient adherence and
satisfaction with therapy.
Maitland D, Jackson A, Osorio J, et al
HIV Med. 2008 Oct;9(8):667-72.
Abstract |
|
|
|
|
|
|
|
|
Abacavir plus Lamivudine: A Review of their Combined Use in the Management
of HIV Infection.
Dando TM, Scott LJ.
Drugs.
2005;65(2):285-302
Abstract |
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
ARV
Drugs Main Page
Main New/Newsworthy
